PER-059-09已完成未知
A Randomized Open-Label, Phase II Study of Lapatinib-capecitabine or Lapatinib-vinorelbine or Lapatinib/Gemcitabine in Subjects With Her2/Neu Amplified Metastatic Breast Cancer Patients Progression After Taxanes Treatment
Grupo Latinoamericano de Investigaciones Clinicas en Oncologica (GLICO),0 个研究点目标入组 0 人开始时间: 2009年11月6日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 70（—）
- 性别
- Female
入选标准
- •The signed informed consent must be obtained in accordance with the requirements of the ethics committee.
- •Subjects must be over 18 years.
- •Histologically confirmed invasive adenocarcinoma of the breast with metastatic or locally advanced disease defined as stage IIIb, lile stage with T4 lesion, or stage IV [according to the 6th AJCC edition].
- •Documented progression after taxane-based treatment for patients with ErbB2 positive metastatic breast cancer for first-line or locally advanced or documented progression after taxane-based regimens as adjuvant therapy. Patients may have had a maximum prior treatment with a chemotherapy regimen for metastatic disease.
- •Patients must have at least 1 definite lesion measurable by RECIST as follows: X-ray, physical examination> 20 mm, Conventional CT scan> 20 mm, Spiral CT scan> 10 mm. Measurable lesions should be outside the field of prior radiotherapy if they are in one place of disease.
- •Disease with over-expression and / or amplification of HER2 / neu confirmed in the local laboratory in the invasive component of the primary or metastatic lesion
- •Previous therapy should include taxane regime.
- •In regions where trastuzumab is available without access barriers, patients must also have received trastuzumab alone or in combination with chemotherapy
- •Previous treatment with anthracyclines in adjuvant / neoadjuvant or metastatic first-line scenarios is allowed if therapy has been discontinued at least 4 weeks before randomization, and all adverse events related to treatment are • Prior treatment with endocrine therapy is allowed if the therapy has been discontinued before randomization, and all adverse events related to treatment are • Previous treatments with radiotherapy for palliative management of metastatic disease, to a limited area (eg, palliative treatment for painful disease) at a different site than the measurable disease and the disease evaluated, it is allowed, however, the subjects must have Treatment completed at least 4 weeks after the last dose of radiotherapy prior to starting the study drugs, and must have recovered from treatment-related toxicities before day 1.11. The life expectancy is at least 6 months.
- •ECOGPSO-2.
- •Patients must have normal organs and marrow function measured within 14 days prior to randomization.
- •Brain tomography / MRI 4 weeks before randomization.
- •Women with potential fertility (WOCBP) must have a negative urine or serum pregnancy test (minimum sensitivity 25 lU / L or equivalent units of HCG) within 7 days prior to registration.
- •Patients must have at least 1 measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST, Therasse, 2000). Medial lesions may be in the field of prior adjuvant radiation. However, there must be at least a 4-week period between the last radiation treatment and baseline Tomography documented the disease status. The documented progression of the irradiated lesion is also required so that the lesion can be considered measurable.
- •Subjects must have a fraction of cardiac ejection in the normal institutional range measured by ECO (echocardiogram) or alternatively by MUGA Tomography (Multigramic Acquisition). The cardiac ejection fraction> 50% and in the normal institutional range demonstrated by echocardiogram or alternatively by MUGA Tomography betwe
排除标准
- •Pregnant or nursing women.
- •Previous therapy with another antiErbb1 or antiErbB2 white agent instead of Trastuzumab only limited by the treatment of V line of metastatic or locally advanced disease OR as adjuvant therapy.
- •Previous exposure to gemcitabine, Vinorelbine and capecitabine for treatment of 1st line of metastatic-recurrent disease OR as adjuvant / neoadjuvant therapy.
- •Treatment in the 14 days prior to randomization with anti-cancer therapy (tumor embolization, chemotherapy, immunotherapy, biological therapy, or hormonal therapy) or mitomycin treatment in the 6 weeks prior to randomization. Such treatment may or may not be resumed after admission to the study. Note: Patients receiving bisphosphonate therapy prior to randomization may continue during their participation in the study, however, bisphosphonates should be initiated following study entry. Prophylactic use of bisphosphonates in subjects without bone disease is not allowed, except for the treatment of osteoporosis.
- •Metastasis in active CNS.
- •Uncontrolled intercurrent disease including, but not limited to, an infection at that time or active, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, serious wound / ulcer / bone fracture that is not cured, or social situations / psychiatric illnesses that may limit the study requirements.
- •Patients with Gi tract disease who are unable to take oral medication, malabsorption syndrome, require EV feeding, previous surgical procedures that affect absorption, uncontrolled inflammatory GI disease (eg, Crohn, ulcerative colitis).
- •Have active liver or biliary disease (with the exception of patients with Gilbert´s syndrome, asymptomatic gallbladder stones, liver metastases or chronic stable liver disease in the investigator´s evaluation).
- •History of another cancer. Subjects who have been disease free for 5 years, or subjects with a history of skin cancer without completely resected melanoma or successfully treated carcinoma in situ are eligible.
- •Dementia, altered mental state, or any physical condition that could prohibit the understanding or signing of informed consent.
- •Concurrent treatment with a research agent or participation in another clinical trial.
- •Use of research drug in 30 days or half-life preceding the first dose of therapy.
- •History of immediate or delayed hypersensitivity or idiosyncrasy to drugs chemically related to Lapatinib or navebumin or capecitabine or gemcitabine and its excipients.
研究者
相似试验
已完成
不适用
A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy as First-line Treatment for Women With HER2-positive and p95HER2-positive Metastatic Breast CancerPER-117-10GlaxoSmithKline,
进行中（未招募）
不适用
A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy versus Trastuzumab Plus Chemotherapy as Firstline Treatment for Women with HER2-positive and p95HER2-positive Metastatic Breast Cancer - n/aEUCTR2010-019390-15-IEGlaxoSmithKline Research & Development Ltd300
进行中（未招募）
不适用
A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy versus Trastuzumab Plus Chemotherapy as Firstline Treatment for Women with HER2-positive and p95HER2-positive Metastatic Breast Cancer - n/aBreast Cancer (HER2-positive and p95HER2-positive metastaticbreast cancer)MedDRA version: 12.1Level: LLTClassification code 10027475Term: Metastatic breast cancerEUCTR2010-019390-15-PLGlaxoSmithKline Research & Development Ltd300
进行中（未招募）
不适用
An open-label, Phase II randomised trial of Lapatinib (TYKERB?) + Pemetrexed (Alimta) versus Pemetrexed in the Second Line Treatment of advanced or metastatic Non Small Cell Lung Cancer - Lapatinib + Pemetrexed vs Pemetrexed in NSCLCEUCTR2007-002472-34-ITGlaxoSmithkine Research and Development Ltd220
进行中（未招募）
1 期
A Phase 2 Randomized Open Label Study of Neratinib versus Lapatinib plus Capecitabine for the treatment of ErbB-2 Positive Locally Advanced or Metastatic Breast Cancerocally advanced or metastatic breast cancerMedDRA version: 15.0 Level: LLT Classification code 10027475 Term: Metastatic breast cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2008-005425-11-DEPuma Biotechnology, Inc233